| [1] |
Suo T, Tong HX, Wan LH, et al. Hyperthermic intraperitoneal chemotherapy for treating peritoneal carcinomatosis from gas-trointestinal cancers: the current situation in the Chinese mainland[J]. Zhongguo Zhong Liu Lin Chuang,2012, 39 (22):1754-6.[锁涛,童汉兴,万柳华,等. 中国大陆腹腔热灌注 化疗治疗胃肠癌腹膜转移癌的现状[J]. 中国肿瘤临床, 2012, 39 (22):1754-6.]
|
| [2] |
Bonenkamp JJ, Sasako M, Hermans J, et al. Tumor load and surgical palliation in gastric cancer[J]. Hepatogastroenterology, 20 01, 48(41): 1219-21.
|
| [3] |
Duarte I, Llanos O. Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach[J]. Hum Pathol, 1981, 12(3): 23 7-42.
|
| [4] |
Moriguchi S, Maehara Y, Korenaga D, et al. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer[J]. Surg Oncol,1992,1(5):341-6..
|
| [5] |
Carneiro F, Sobrinho-Sim?es M. Metastatic pattern of gastric carcinoma[J]. Hum Pathol,1996,27(2):213-4.
|
| [6] |
Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with peritoneal seeding: best palliation with a ray of hope for cure[J]. Oncology,2000,58(2):96-107.
|
| [7] |
Piessen G, Messager M, Leteurtre E, et al. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation[J]. Ann Surg,2009,250(6):878-87.
|
| [8] |
Jiang CG, Wang ZN, Sun Z, et al. Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: results from a Chinese mono-institutional study[J]. J Surg Oncol,2011,103(7):700-3.
|
| [9] |
Yamasaki J, Experimental study of 5-fluorouracil microspherespreparation and therapeutic effect on peritoneal carcinomatosis[J]. J. Kyoto Pref. Univ. Med, 1997,106(11): 1091-8.
|
| [10] |
Hagiwara A, Sakakura C, Tsujimoto H, et al. New formulation of 5-fluorouracil in microspheres reduces toxicity in mice[J]. Anticancer Drugs,1996, 7(7): 780-4.
|
| [11] |
Bissery MC, Nohynek G, Sanrerink GJ, et al. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience[J]. Anticancer Drugs,1995,6(3): 339-55, 36 3-8.
|
| [12] |
Tanaka M, Obata T, Sasaki T. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo[J]. Eur J Cancer,1996,32A (2): 226-30.
|
| [13] |
Han LH, Tsuyoshi T, Huang YN, et al. Toxicity of intraperitoneal docetaxol microspheres in mice[J]. J Kyoto Pref Univ Med[J], 20 02, 111(8): 681-4.
|
| [14] |
Hagiwara A, Sakakura C, Yamasaki J, et al. Dextran sulfate inhibits injured abdominal wall-specific tumor implantation in mice[J]. Anticancer Drugs, 2000, 11(10): 873-7.
|
| [15] |
Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma[J]. Br J Surg, 2000, 87(2):236-42.
|
| [16] |
Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy[J]. Ann Surg Oncol, 2002, 9( 4):394-400.
|
| [17] |
D’Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma[J]. Ann Surg, 2004, 240(5):808-16.
|
| [18] |
Koppe MJ, Boerman OC, Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies[J]. Ann Surg, 2006, 243(2):212-22.
|
| [19] |
Glehen O, Osinsky D, Beaujard AC, et al. Natural history of peritoneal carcinomatosis from nongynecologic malignancies[J]. Surg Oncol Clin N Am, 2003, 12(3):729-39.
|
| [20] |
Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors[J]. Cancer, 1989, 63(2):364-7.
|
下载:
